TOP TEN perturbations for 1553009_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553009_s_at
Selected probe(set): 1553009_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553009_s_at (1553009_s_at) across 6672 perturbations tested by GENEVESTIGATOR:

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):1.4240084
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)

Relative Expression (log2-ratio):1.3420038
Number of Samples:2 / 5
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary.

expO breast cancer study 1 (intraductal carcinoma; in situ) / expO breast cancer study 1 (ductal and lobular carcinoma; primary)

Relative Expression (log2-ratio):-1.2375288
Number of Samples:3 / 4
Experimental expO breast cancer study 1 (intraductal carcinoma; in situ)
Tumor tissue samples obtained from the breast of patients with intraductal carcinoma.
Control expO breast cancer study 1 (ductal and lobular carcinoma; primary)
Primary tumor tissue samples obtained from the breast of patients with ductal and lobular carcinoma.

glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-1.0346651
Number of Samples:2 / 4
Experimental glioma study 17 ( small cell glioblastoma; unsorted)
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

thyroid eye disease study 1 (lacrimal gland tissue) / normal lacrimal gland tissue

Relative Expression (log2-ratio):0.99656296
Number of Samples:7 / 7
Experimental thyroid eye disease study 1 (lacrimal gland tissue)
Lacrimal gland tissue samples obtained from patients who suffered from thyroid eye disease (TED). Biopsies were formalin-fixed and paraffin-embedded.
Control normal lacrimal gland tissue
Normal lacrimal gland tissue samples. The control tissue was obtained during surgery on eyes with non-inflamed orbits, such as blepharoplasties and enucleations. Biopsies were formalin-fixed and paraffin-embedded.

pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)

Relative Expression (log2-ratio):0.9574766
Number of Samples:8 / 30
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control pediatric septic shock study 3 (infant)
Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive.

expO connective/soft tissue cancer study 1 (myxoid liposarcoma; metastatic) / expO connective/soft tissue cancer study 1 (fibrous histiocytoma, malignant; metastatic)

Relative Expression (log2-ratio):0.9459238
Number of Samples:2 / 5
Experimental expO connective/soft tissue cancer study 1 (myxoid liposarcoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary myxoid liposarcoma of the connective and soft tissue.
Control expO connective/soft tissue cancer study 1 (fibrous histiocytoma, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary malignant fibrous histiocytoma of the connective and soft tissue.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-0.9173832
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):-0.9118738
Number of Samples:22 / 2
Experimental expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the kidney of patients with papillary adenocarcinoma (NOS).
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)

Relative Expression (log2-ratio):0.89868164
Number of Samples:8 / 5
Experimental expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary.
Control expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary.